ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

Sanofi Sells Dermik Unit To Valeant For $425 Million

PARIS -(Dow Jones)- French pharmaceutical giant Sanofi SA (SAN.FR) said Monday it sold Dermik, its dermatology unit, to Canada-based Valeant Pharmaceuticals International Inc. (VRX) for $425 million in cash. The transaction involves Dermik assets, comprising an aesthetic and therapeutic dermatology business in the U.S. and Canada and an aesthetic dermatology business in other parts of the world, which had sales of $206 million in 2010, Sanofi said. Dermik has a significant presence in the medical dermatology market in the U.S. and Canada, with a strong field force and well-known brands, which include BenzaClin, Carac and Sculptra. Sanofi decided to sell Dermik to focus on its "growth platforms" and "innovation." The French company recently bought U.S. biotech firm Genzyme for $20 billion and a string of smaller firms prior to the Genzyme takeover. The transaction will still have to be cleared by certain antitrust authorities and meet other customary conditions. -By Inti Landauro, Dow Jones Newswires; +33 1 4017 1740; inti.landauro@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
03/27/201718:23:00Valeant Ex-CEO Pearson Sues Company Over Unpaid Stock
03/24/201703:02:00Valeant Paid CEO $62.7 Million Total -- WSJ
03/23/201718:45:00Valeant CEO Joseph Papa Was Paid $62.7 Million in 2016 -- 4th...
03/23/201714:44:00Valeant CEO Joseph Papa Was Paid $62.7 Million in 2016 -- 3rd...
03/23/201713:51:00Valeant CEO Joseph Papa Was Paid $62.7 Million in 2016 -- 3rd...
03/23/201712:01:00Valeant CEO Joseph Papa Was Paid $62.7 Million in 2016 -- 2nd...
03/23/201711:35:00Valeant CEO Joseph Papa Was Paid $62.7 Million in 2016 -- Update
03/23/201710:11:00Valeant CEO Joseph Papa Was Paid $62.7 Million in 2016
03/23/201708:05:22Proxy Statement (definitive) (def 14a)
03/21/201716:51:10Current Report Filing (8-k)
03/21/201716:30:00Valeant Completes Refinancing Transactions
03/21/201716:30:00Valeant Completes Refinancing Transactions
03/20/201721:45:00Valeant Announces the Early Results of Tender Offers for Its...
03/20/201721:45:00Valeant Announces the Early Results of Tender Offers for Its...
03/20/201717:00:00Bausch + Lomb And Nicox Announce PDUFA Date For Novel Glaucoma...
03/20/201717:00:00Bausch + Lomb And Nicox Announce PDUFA Date For Novel Glaucoma...
03/17/201716:24:22Current Report Filing (8-k)
03/16/201717:13:47Statement of Changes in Beneficial Ownership (4)
03/16/201717:06:04Statement of Changes in Beneficial Ownership (4)
03/16/201716:43:41Statement of Beneficial Ownership (sc 13d)

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US